开元棋牌电脑 |本期目录/Table of Contents|

[1]杨大勇,李琳.雷珠单抗联合激光光凝术治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿疗效观察[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2019,39(4):369-372.[doi:10.13389/j.cnki.rao.2019.0084]
 YANG Da-Yong,LI Lin.Ranibizumab combined with laser photocoagulation in the treatment of patients with macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(4):369-372.[doi:10.13389/j.cnki.rao.2019.0084]
点击复制

雷珠单抗联合激光光凝术治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿疗效观察(/HTML)
分享到:

《开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年4期
页码:
369-372
栏目:
应用研究
出版日期:
2019-04-05

文章信息/Info

Title:
Ranibizumab combined with laser photocoagulation in the treatment of patients with macular edema secondary to branch retinal vein occlusion
作者:
杨大勇李琳
010050 内蒙古自治区呼和浩特市,内蒙古医科大学附属医院眼科
Author(s):
YANG Da-YongLI Lin
Department of Ophthalmology,Affiliated Hospital of Inner Mongolia Medical University,Huhehaote 010050,Inner Mongolia Autonomous Region,China
关键词:
雷珠单抗激光光凝术视网膜分支静脉阻塞黄斑水肿疗效安全性
Keywords:
ranibizumablaser photocoagulationbranch retinal vein occlusionmacular edemaclinical effectssafety
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2019.0084
文献标志码:
A
摘要:
目的 探讨雷珠单抗联合激光光凝术治疗视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)继发黄斑水肿疗效。方法 选取我院2015年1月至2016年12月收治BRVO继发黄斑水肿患者共90例,随机分为A组(30例)、B组(30例)及C组(30例),分别采用雷珠单抗单纯玻璃体内注射、单纯激光光凝术及雷珠单抗玻璃体内注射+激光光凝术治疗;比较3组患者治疗前后最佳矫正视力(best corrected visual acuity,BCVA)、黄斑中心凹厚度(central macular thickness,CMT)、眼压及并发症发生率。结果 A组治疗后3个月、6个月及12个月BCVA分别为0.80±0.12、0.72±0.08、0.67±0.06;B组治疗后3个月、6个月及12个月BCVA分别为0.63±0.09、0.60±0.06、0.47±0.04;C组治疗后3个月、6个月及12个月BCVA分别为0.59±0.06、0.54±0.05、0.43±0.04;B、C组患者治疗后3个月、6个月及12个月BCVA均显着低于A组(F=2.51、2.68、2.91,P=0.03、0.02、0.02)。A组治疗后3个月、6个月及12个月CMT分别为(359.15±77.95)μm、(365.27±53.38)μm、(300.25±39.01)μm;B组治疗后3个月、6个月及12个月CMT分别为(304.32±59.20)μm、(327.68±40.91)μm、(246.23±30.04)μm;C组治疗后3个月、6个月及12个月CMT分别为(209.30±54.39)μm、(264.33±37.80)μm、(208.17±29.34)μm;B、C组治疗后3个月、6个月及12个月CMT均显着小于A组(F=3.78、4.66、5.14,均为P=0.00)。3组患者治疗后3个月眼压比较差异无统计学意义(F=0.95,P=0.64);C组患者治疗后6个月和12个月眼压均显着低于A、B组(F=2.45、2.60,P=0.03、0.02)。3组患者术后并发症发生率差异无统计学意义(χ2=2.14,P=0.38)。结论 相较于单纯应用激光光凝术和雷珠单抗玻璃体内注射术,雷珠单抗玻璃体内注射+激光光凝术治疗BRVO继发黄斑水肿可有效改善视力,降低CMT,且未加重并发症发生风险。
Abstract:
Objective To investigate the efficacy of laser photocoagulation and ranibizumab for the treatment of patients with macular edema secondary to branch retinal vein occlusion (BRVO).Methods Totally 90 patients with macular edema secondary to BRVO were chosen in the period from January 2015 to December 2016 in our hospital and randomly divided into 3 groups including A group (30 patients) undergoing ranibizumab administration alone and B group (30 patients) receiving laser photocoagulation alone and C group (30 patients) receiving both ranibizumab administration with laser photocoagulation;and the levels of the best corrected visual acuity (BCVA) and central macular thickness (CMT) and eye pressure before and after treatment and the complications incidence of the three groups were compared.Results The levels of BCVA of A group in 3 months,6 months and 12 months after treatment were 0.80±0.12,0.72±0.08,0.67±0.06,respectively;the levels of BCVA of B group in 3 months,6 months and 12 months after treatment were 0.63±0.09,0.60±0.06,0.47±0.04,respectively;the levels of BCVA of C group in 3 months,6 months and 12 months after treatment were 0.59±0.06,0.54±0.05,0.43±0.04,respectively.The levels of BCVA of B group and C group in 3 months,6 months and 12 months after treatment were significant better than A group(F=2.51,2.68,2.91,P=0.03,0.02,0.02).The levels of CMT of A group,B group and C group in 3 months,6 months and 12 months after treatment were(359.15±77.95)μm,(365.27±53.38)μm,(300.25±39.01)μm;(304.32±59.20)μm,(327.68±40.91)μm,(246.23±30.04)μm and(209.30±54.39)μm,(264.33±37.80)μm,(208.17±29.34)μm.The levels of CMT of B group and C group in 3 months,6 months and 12 months after treatment were significant better than those of A group(F=3.78,4.66,5.14,all P=0.00,0.00,0.00).There was no significant difference in the eye pressure in 3 months after treatment among the 3 groups(F=0.95,P=0.64).The eye pressure of B group and C group in 6 and 12 months after treatment were significant better than that of A group(F=2.45,2.60,P=0.03,0.02).There was no significant difference in the complications incidence among the 3 groups (χ2=2.14,P=0.38).Conclusion Compared with laser photocoagulation and ranibizumab administration alone,the combination methods for the treatment of patients with macular edema secondary to BRVO can achieve efficiently higher visual acuity,reduce the levels of CMT.

参考文献/References:

[1] SHOEIBI N,AHMADIEH H,ENTERZARI M,YASERI M.Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema:long-term results of a clinical trial[J].J Ophthalmic Vis Res,2013,8(2):99-106.
[2] LIU X,ZHOU X,WANG Z,LI T,JIANG B.Intravitreal bevacizumab with or without triamcinolone acetonide for diabetic macular edema:a meta-analysis of randomized controlled trials[J].Chin Med J(Engl),2014,127(19):3471-3476.
[3] JIN E,LUO L,BAI Y,ZHAO M.Comparative effectiveness of intravitreal bevacizumab with or without triamcinolone acetonide for treatment of diabetic macular edema[J].Ann Pharmacother,2015,49(4):387-397.
[4] STEFANINI F R,BADARO E,FALABELLA P,KOSS M,FARAH M E,MAIA M.Anti-VEGF for the management of diabetic macular edema[J].J Immunol Res,2014,20(14):632307.
[5] LI X X,WANG N L.Ophthalmology[M].Beijing:People’s Health Publishing House,2016:102-103.
黎晓新,王宁利.眼科学[M].北京:人民卫生出版社,2016:102-103.
[6] CAMPOCHIARO P A,WYKOFF C C,SHAPIRO H,RUBIO R G,EHRLICH J S.Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema[J].Ophthalmology,2014,121(9):1783-1789.
[7] YOLCU U,SOBACI G.The effect of combined treatment of bevacizumab and triamcinolone for diabetic macular edema refractory to previous intravitreal mono-injections[J].Int Ophthalmol,2014,34(4):845-849.
[8] ELMAN M J,AYALA A,BRESSLER N M,BROWNING D,FLAXEl C J,GLASSMAN A R,et al.Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment:5-year randomized trial results[J].Ophthalmology,2015,122(2):375-381.
[9] ZHANG Y,MA J,MENG N,LI H,QU Y.Comparison of intravitreal triamcinolone acetonide with intravitreal bevacizumab for treatment of diabetic macular edema:a meta-analysis[J].Curr Eye Res,2013,38(5):578-587.
[10] GUPTA N,MANSOOR S,SHARMA A,SAPKAL A,SHETH J,FALATOONZAEDH P,et al.Diabetic retinopathy and VEGF[J].Open Ophthalmol J,2013,7(3):4-10.
[11] EVOY K E,ABEL S R.Ranibizumab:the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema[J].Ann Pharmacother,2013,47(6):811-818.
[12] LI J,CUI Y,WANG Q,GUO D D,PAN X M,WANG X G,et al.The proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1[J].Mol Vis,2014,20(13):649-660.
[13] ZHANG X,ZENG H,BAO S,WANG N G,GILLIES M C.Diabetic macular edema:new concepts in patho-physiology and treatment[J].Cell Biosci,2014,20(Suppl 1):27-33.
[14] CALLANAN D G,GUPATA S,BOYER D S,CIULLA T A,SINGER M A,KUPPERMANN B D,et al.Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema[J].Ophthalmology,2013,120(9):1843-1851.
[15] LIU X D,ZOU X D,WANG Z,SHEN Y M.Macular laser photocoagulation with or without intravitreal triamcinolone pretreatment for diabetic macular edema:a result from five randomized controlled trials[J].Int J Ophthalmol,2016,9(1):132-138.
[16] MIITCHELL P,WONG T Y;Diabetic Macular Edema Treatment Guideline Working Group.Management paradigms for diabetic macular edema[J].Am J Ophthalmol,2014,157(3):505-513.

相似文献/References:

[1]李姣 王兴荣 崔彦 刘正峰 王影 李洋.雷珠单抗选择性体外抑制睫状体恶性黑色素瘤[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2013,33(11):.
[2]陈芳,宁红珠,曾琼英,等.532nm激光光凝治疗视网膜前出血的临床观察[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2014,34(5):480.[doi:10.13389/j.cnki.rao.2014.0132]
 CHEN Fang,NING Hong-Zhu,ZENG Qiong-Ying,et al.Clinical observation of 532 nm laser photocoagulation for pre-retinal hemorrhage[J].Recent Advances in Ophthalmology,2014,34(4):480.[doi:10.13389/j.cnki.rao.2014.0132]
[3]刘彩霞,谢青,生侠,等.激光光凝术治疗糖尿病视网膜病变时机的选择与治疗效果的相关性研究[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2014,34(6):575.[doi:10.13389/j.cnki.rao.2014.0158]
 [J].Recent Advances in Ophthalmology,2014,34(4):575.[doi:10.13389/j.cnki.rao.2014.0158]
[4]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗(Ranibizumab)治疗视网膜静脉阻塞继发黄斑水肿[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
 [J].Recent Advances in Ophthalmology,2014,34(4):855.[doi:10.13389/j.cnki.rao.2014.0236]
[5]张聪,刘东宁,徐丽. 玻璃体内注射Lucentis治疗中心性渗出性脉络膜视网膜病变的临床疗效[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2014,34(9):864.[doi:10.13389/j.cnki.rao.2014.0239]
 [J].Recent Advances in Ophthalmology,2014,34(4):864.[doi:10.13389/j.cnki.rao.2014.0239]
[6]章晖,叶波,邱新文,等.雷珠单抗辅助23G玻璃体切割术治疗增生性糖尿病视网膜病变[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2014,34(10):975.[doi:10.13389/j.cnki.rao.2014.0270]
 [J].Recent Advances in Ophthalmology,2014,34(4):975.[doi:10.13389/j.cnki.rao.2014.0270]
[7]王博,吴京,马明,等. 玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2015,35(3):246.[doi:10.13389/j.cnki.rao.2015.0066]
 WANG Bo,WU Jing,MA Ming,et al. Clinictid effect comparison of intravitreal lucentis and triamcinolone acetonide for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(4):246.[doi:10.13389/j.cnki.rao.2015.0066]
[8]刘斌,杨玉霞,刘杏,等. 雷珠单抗联合Ahmed青光眼阀植入术治疗新生血管性青光眼[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2015,35(3):263.[doi:10.13389/j.cnki.rao.2015.0070]
 LIU Bin,YANG Yu-Xia,LIU Xing,et al. Intravitreal lucentis injection combined with Ahmed valve implantation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(4):263.[doi:10.13389/j.cnki.rao.2015.0070]
[9]刘志南,邓国华,江一. 光凝前雷珠单抗玻璃体内注射对CNV患者黄斑区视网膜及视功能的影响[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2015,35(4):365.[doi:10.13389/j.cnki.rao.2015.0098]
 LIU Zhi-Nan,DENG Guo-Hua,JIANG Yi. Effects of ranibizumab intravitreal injection before photocoagulation on macular retina and visual function in patients with CNV[J].Recent Advances in Ophthalmology,2015,35(4):365.[doi:10.13389/j.cnki.rao.2015.0098]
[10]万文萃,刘宇莹,尹向可,等. 玻璃体内注射抗血管内皮生长因子药物治疗急进性后部型早产儿视网膜病变[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2015,35(6):554.[doi:10.13389/j.cnki.rao.2015.0150]
 WAN Wen-Cui,LIU Yu-Ying,YIN Xiang-Ke,et al. Intravitreal injection of ranibizumab for aggressive posterior retinopathy of prematurity[J].Recent Advances in Ophthalmology,2015,35(4):554.[doi:10.13389/j.cnki.rao.2015.0150]
[11]李素华,高永峰. 比较单独黄斑局灶/格栅样光凝术和联合雷珠单抗治疗糖尿病性黄斑水肿的疗效[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2015,35(6):566.[doi:10.13389/j.cnki.rao.2015.0153]
 LI Su-Hua,GAO Yong-Feng. Efficacy of macular focal / grid photocoagulation combined with ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(4):566.[doi:10.13389/j.cnki.rao.2015.0153]

备注/Memo

备注/Memo:
更新日期/Last Update: 2019-04-15